English
Specials
    Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsAurobindopharma

    At Moneycontrol, the Results page helps you effectively track corporate announcements and results for various listed companies across both India and abroad. With our Results page, you can keep abreast with an updated, comprehensive view of all the profit/loss statements, company spendings, AGM outcomes, and quarterly and annual results from all these listed companies. Additionally, Moneycontrol also regularly tracks international MNCs listed on NASDAQ and Asian bourses, including popular companies like Apple, Google, Alibaba. Apart from finding solid copies of company results, stock movements consequent to these company results, expectations, and analytical post results copies, you will also find copies and articles detailing the earnings, impact, and all major announcements made to media/exchanges by these companies, so that you do not miss anything. We also provide you with concrete data points to help you spot profitable trades, stock build-ups, and bulk deals. At Moneycontrol, we also cover analysts/investors meetings; scrutinise results and data and BSE/NSE reports or news. The copies are not just full of information and data, but are also adequately supplemented with expert views, investor opinions, extensive interviews, videos, and a huge variety of explainers, analyses, and informative slideshows to help you gauge the market and make investment decisions in the best possible manner. More

    Jump to
    • Aurobindo Q3 profit seen up 38%, US biz may support revenue

      Aurobindo Q3 profit seen up 38%, US biz may support revenue

      Operating profit (earnings before interest, tax, depreciation and amortisation) in Q3 is likely to jump 40 percent to Rs 857 crore and margin may expand 430 basis points to 23.6 percent compared to year-ago period.

    • Aurobindo Q2 profit seen up 25%, US biz may grow over 30%

      Aurobindo Q2 profit seen up 25%, US biz may grow over 30%

      US business, which is around 58 percent of formulation sales, is likely to grow over 30 percent led by more than 20 ANDA (abbreviated new drug application) launches over last six months (including Suprax - used for treatment of bacterial infections - in Q1).

    • Aurobindo Q1 profit seen up 8%, EBITDA margin may contract

      Aurobindo Q1 profit seen up 8%, EBITDA margin may contract

      During June quarter, revenue growth may be aided by improving US and anti-retrovirals (ARV) sales. US business (which contributes around 50 percent to sales) is expected to grow 25-30 percent on the back of 5-6 ANDA launches (including Suprax

    • Aurobindo Pharma Q4 profit seen down 19% to Rs 408 cr: Poll

      Aurobindo Pharma Q4 profit seen down 19% to Rs 408 cr: Poll

      Aurobindo Pharma's fourth quarter profit is seen falling 19 percent year-on-year to Rs 408 crore, according to a CNBC-TV18 poll.

    • Aurobindo Pharma: Fabulous Q3

      Aurobindo Pharma: Fabulous Q3

      Aurobindo Pharma came out with a great set of numbers this quarter.

    • Aurobindo Q3 net profit up 355% to Rs 417cr

      Aurobindo Q3 net profit up 355% to Rs 417cr

      Aurobindo Pharma surpassed all street expectations in third quarter FY14 with highest ever profit numbers. A healthy and improved product mix and increase in sale of high margin products has pushed profitability higher for the company, reports CNBC TV18‘s Archana Shukla.

    • Aurobindo Pharma Q2 net loss seen at Rs 16.7cr: P Lilladher

      Aurobindo Pharma Q2 net loss seen at Rs 16.7cr: P Lilladher

      Sales of Aurobindo Pharma are expected to increase by 7.7 percent QoQ (up 22.1 percent YoY) to Rs 1,831.3 crore, according to Prabhudas Lilladher.

    • Aurobindo Pharma Q1 net may rise 176% at Rs 137.5 cr: Emkay

      Aurobindo Pharma Q1 net may rise 176% at Rs 137.5 cr: Emkay

      Emkay Equity Advisory expects Aurobindo Pharma to report a 25.5 percent growth quarter-on-quarter (rise of 175.6 percent year-on-year) in net profit at Rs 137.5 crore.

    • Aurobindo Pharma Q1 PAT may dip 103% at Rs 4cr: P Lilladher

      Aurobindo Pharma Q1 PAT may dip 103% at Rs 4cr: P Lilladher

      Prabhudas Lilladher expects Aurobindo Pharma to report a 96.1 percent degrowth quarter-on-quarter (fall of 103.3 percent year-on-year) in net profit at Rs 4.2 crore.

    • Aurobindo Pharma Q1: Analysts expect profit at Rs 75 cr

      Aurobindo Pharma Q1: Analysts expect profit at Rs 75 cr

      Aurobindo Pharma is set to announce its results for the quarter ended June 2012 today. Analysts on an average expect the company to report profit after tax of around Rs 75 crore during the quarter as against loss of Rs 122 crore in a year ago period, but the PAT is likely to fall by 30.55% quarter-on-quarter.

    • Pharmaceutical results preview for Q3FY12: Emkay

      Pharmaceutical results preview for Q3FY12: Emkay

      Emkay Global Financial Services has come with its December quarterly earning estimates for pharmaceutical sector. According to the research firm the sector is expected to report a growth of 18% YoY (5% QoQ) in revenues partly driven by Rupee depreciation which is likely to be 4-5% of the overall growth.

    • Aurobindo Sept qtr PAT seen at Rs 192cr: Angel

      Aurobindo Sept qtr PAT seen at Rs 192cr: Angel

      Angel Broking has come out with its earning estimates on pharma sector for the quarter ended September 2011. According to the research firm, Aurobindo Pharma September quarter net sales are expected to go up by 18.7% at Rs 1,238 crore, year-on-year, (YoY) basis.

    • Mid-sized pharma margins to crimp despite sales

      Mid-sized pharma margins to crimp despite sales

      Mid-sized Indian drugmakers are expected to post steady to strong revenue growth in April-June, riding healthy domestic and overseas demand, but higher would crimp margins.

    • Aurobindo Pharma FY11 PAT seen dn 0.35% at Rs 561 cr

      Aurobindo Pharma FY11 PAT seen dn 0.35% at Rs 561 cr

      Aurobindo Pharma is to announce its FY11 revenues are seen up 20% at Rs 4276 crore versus Rs 3575 crore.

    • Aurobindo Dec qtr PAT seen up 40% at Rs 145cr: Angel

      Aurobindo Dec qtr PAT seen up 40% at Rs 145cr: Angel

      Angel Broking has come out with its earning estimates on the pharmaceutical sector for the quarter ended December 2010. According to the research firm, Aurobindo Pharma December quarter net sales are expected to go up by 11% to Rs 935 crore, Year-on-Year, (Y-o-Y) basis.

    • Aurobindo Pharma Dec qtr PAT seen down at Rs 157.2cr: Karvy

      Aurobindo Pharma Dec qtr PAT seen down at Rs 157.2cr: Karvy

      Karvy Stock Broking has come out with its earning estimates on pharma sector for the quarter ended December 2010. According to the research firm, Aurobindo Pharmaceuticals December quarter sales are expected to go up by 23.4% at Rs 1129.9 crore, Year-on-Year, (YoY) basis.

    • Aurobindo Pharm Dec qtr PAT seen up at Rs 156.9cr: Emkay

      Aurobindo Pharm Dec qtr PAT seen up at Rs 156.9cr: Emkay

      Emkay Global Financial Services has come out with its earning estimates on pharma sector for the quarter ended December 2010. According to the research firm, Aurobindo Pharm December quarter sales are expected to go up by 23% to Rs 1125.9 crore, Year-on-Year, (Y-o-Y) basis.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347